TGFB1 and melanoma: Likewise, GC1008 (a human anti-TGF-β monoclonal antibody that neutralizes all isoforms of TGF-β) had an acceptable safety profile and showed preliminary evidence of antitumor activity in pre-treated stage IV melanoma patients (Morris et al., 2014).